Variant position: 70 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 465 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human HEEASVKMLPTYVRSTPEGS EVGDFLSLDLGGTNFRVMLVK
Mouse HQEASVKMLPTYVRSTPEGS EVGDFLSLDLGGTNFRVMLVK
Rat HEEASVKMLPTYVRSTPEGS EVGDFLSLDLGGTNFRVMLVK
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 465 Glucokinase
10 – 454 Hexokinase
67 – 203 Hexokinase small subdomain
64 – 64 S -> P. Increased glucokinase activity based on measure of catalytic efficiency. Increased affinity for glucose.
Structure/function studies of human beta-cell glucokinase. Enzymatic properties of a sequence polymorphism, mutations associated with diabetes, and other site-directed mutants.
Takeda J.; Gidh-Jain M.; Xu L.Z.; Froguel P.; Velho G.; Vaxillaire M.; Cohen D.; Shimada F.; Makino H.; Nishi S.; Stoffel M.; Vionnet N.; St Charles R.; Harrison R.W.; Weber I.T.; Bell G.I.; Pilkis S.J.;
J. Biol. Chem. 268:15200-15204(1993)
Cited for: VARIANT ASN-4; VARIANTS MODY2 LYS-70; PRO-131; THR-188; ARG-257 AND GLU-414; MUTAGENESIS OF GLU-177; GLU-256 AND LYS-414; CATALYTIC ACTIVITY; FUNCTION;
Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain.
Estalella I.; Rica I.; Perez de Nanclares G.; Bilbao J.R.; Vazquez J.A.; San Pedro J.I.; Busturia M.A.; Castano L.;
Clin. Endocrinol. (Oxf.) 67:538-546(2007)
Cited for: VARIANTS MODY2 GLU-16; ASN-19; PRO-20; TRP-36; SER-43; SER-44; 61-TYR--GLN-465 DEL; SER-61; LYS-70; ARG-72; PRO-77; GLU-78; ASP-80; ILE-82; HIS-108; PRO-116; LEU-182; 186-ARG--GLN-465 DEL; TYR-187; TRP-191; LEU-200; THR-202; MET-206; MET-209; SER-223; ARG-224; SER-227; MET-228; ARG-233; 234-TYR--GLN-465 DEL; GLY-252; ALA-255; LYS-256; ARG-261; LYS-265; LYS-298; TRP-308; HIS-377; VAL-379; LEU-383; 399-GLU--GLN-465 DEL; PHE-411; PRO-416; GLU-420 AND TRP-441;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.